Navigating the Glofitamab CRL and Bispecifics’ Place in Lymphoma
Tycel Phillips, MD, spoke about the impact the glofitamab CRL had on the landscape of bispecifics in lymphoma.
Previous Post
First-Ever Case Report Highlights Potential for Acute Retinal Necrosis While on Dimethyl Fumarate
Next Post
Addition of Radiotherapy to Systemic Chemotherapy Improves Survival in ESCC
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago